Antiviral Development

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections.

Our Science

Pharmasset’s primary focus is on the development of oral therapeutics for the treatment of:

• Hepatitis B
• Hepatitis C
• HIV

Product Candidates

Pharmasset currently has three product candidates that we are developing ourselves or with a strategic partner:

• Clevudine for HBV
• R7128 for HCV
• Racivir for HIV
• Discovery